Imprimis Phar (NQ: IMMY )
5.690 USD UNCHANGED Last Price Updated: 4:06 PM EST, Dec 31, 2018 Add to My Watchlist
Stories about Imprimis Phar
More Than 100% Upside Seen In Imprimis After Q4 Results
March 22, 2017
Imprimis Pharmaceuticals Inc (NASDAQ: IMMY), a nano-cap pharmaceutical company that owns, markets and dispenses a portfolio of ...
Imprimis Challenges Mallinckrodt's Acthar
March 21, 2017
Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) wants to stop egregious drug pricing issues, and Mallinckrodt PLC (NYSE: MNK) is its next ...
BRIEF-Imprimis Pharmaceuticals files for offering of up to 10.73 mln shares by selling stockholders
January 23, 2017
* Files for offering of up to aggregate of 10.73 million shares of co's common stock by the selling stockholders Source text for Eikon: Further company coverage:
BRIEF-Imprimis Pharmaceuticals says it raised about $10 million
December 30, 2016
* Imprimis Pharmaceuticals says it raised about $10 million in equity, options and warrant financing - SEC filing Source text: (http://bit.ly/2im320x) Further company coverage:
BRIEF-Imprimis Pharmaceuticals says entered into third amendment to loan and security agreement dated May 11
December 29, 2016
* Imprimis Pharmaceuticals-amendment allowed to exchange $3 million principal balance convertible note dated Jan 22, 2016 for $3 million term loan-sec filing
15 Biggest Mid-Day Gainers For Thursday
December 22, 2016
Tokai Pharmaceuticals Inc (NASDAQ: TKAI) shares jumped 53.5 percent to $1.55. Tokai Pharmaceuticals and Otic Pharma disclosed ...
18 Stocks Moving In Thursday's Pre-Market Session
December 22, 2016
Gainers Globalstar, Inc. (NYSE: GSAT) rose 22.5 percent to $1.80 in pre-market trading following a report that a revised ...
* Has agreed to sell an aggregate of approximately 5.1 million units at a purchase price of $1.915 per unit
Imprimis CEO Talks Phenomenal Quarter: 'Shocking' Statistics, Simplification And A Trifecta For Success
December 01, 2016
Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) is a San Diego-based small-cap pharmaceutical company that specializes in the ophthalmology ...
Benzinga's Top Initiations
November 28, 2016
Analysts at Citigroup initiated coverage on Johnson Controls International plc (NYSE: JCI) with a Buy rating. The ...
The Market In 5 Minutes: Castro, Trump And Oil In Focus
November 28, 2016
Macro Focus Futures for the Dow Jones Industrial Average fell 63 points to 19,081.00, while the Standard & Poor’s 500 ...
Imprimis Signs Agreement With One Of Nation's Largest Pharmacy Benefit Managers; CEO Talks Disruption
November 22, 2016
Pharmaceutical compounder Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) first stepped onto the national stage in December 2015, when the ...
* Imprimis pharmaceuticals registers its new jersey facility with the fda as an outsourcing facility
* Imprimis' Dropless Therapy shows significant advantages in a large peer-reviewed study Source text for Eikon: Further company coverage: (Bangalore.firstname.lastname@example.org)
The Anti-Price Gouging Lead Poisoning Treatment
October 18, 2016
Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) announced Monday that it has a new trick up its sleeve to treat lead poisoning. The company ...
BRIEF-Imprimis reports availability of lower-cost option for the treatment of lead poisoning
October 17, 2016
* Imprimis Pharmaceuticals announces availability of lower-cost option for the treatment of lead poisoning
BRIEF-Imprimis Pharmaceuticals implemented an expense reduction program
September 26, 2016
Benzinga Talks With Imprimis Pharmaceuticals' CEO About Earnings, MKO Melt, Drug Pricing And More
August 22, 2016
Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) owns, markets and dispenses a portfolio of compounded therapeutic in various areas, ...
Below is a tool used by the Benzinga News Desk each trading day -- it's a look at everything happening in the market, in five ...
BRIEF-Imprimis Pharmaceuticals Q2 revenue $4.9 million
August 15, 2016
* Agreement covers sale and leaseback of Imprimis' drug manufacturing equipment and has an initial term of up to three years
Benzinga recently had the chance to speak with Imprimis Pharmaceuticals Inc (NASDAQ: IMMY)’s Founder and CEO, Mark L. Baum ...
5 Pharmaceuticals Stocks to Sell Now
April 29, 2016
* Imprimis pharmaceuticals inc says filed for registration of its ImprimisRx TX pharmacy, in allen, texas , with fda as a 503b outsourcing facility Source text for Eikon: Further company coverage:...
Earnings Scheduled For March 23, 2016
March 22, 2016
General Mills, Inc. (NYSE: GIS) is estimated to report its quarterly earnings at $0.62 per share on revenue of $4.08 ...
Imprimis Pharma CEO Talks Valeant Price 'Jacking,' Says His Co. Will Double Revenue This Quarter
March 09, 2016
Imprimis Pharmaceuticals (NASDAQ: IMMY) is a growing player in the ophthalmology eye drop market. Benzinga recently spoke with ...
JMP Securities Defends Retrophin, Believes It's Well Positioned To Defend Thiola Franchise From Imprimis Pharma Competition
February 22, 2016
JMP Securities’ Lisa A Bayko maintained a Market Outperform rating for Retrophin Inc. (NASDAQ: RTRX), with a price target of ...
9 Pharmaceuticals Stocks to Sell Now
February 18, 2016
Imprimis Pharma to make cheaper alternative to Retrophin's Thiola
February 10, 2016
Feb 10 (Reuters) - Compounding pharmacy Imprimis Pharmaceuticals Inc said on Wednesday it plans to make a cheaper alternative to Retrophin Inc's kidney stone drug, Thiola.